Vericel
 | This article relies on a single source. (November 2025) |
| Formerly | Aastrom Biosciences, Inc. |
|---|---|
| Type | Public |
| Nasdaq: VCEL Russell 2000 component S&P 600 component | |
| Industry | Biotechnology |
| Founded | 1989 in Ann Arbor, Michigan, United States |
| Headquarters | , United States |
Number of locations | 2 |
Key people | |
| Products |
|
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.[1]
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011.[1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.[1]
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.[1]
References
[edit]- 1 2 3 4 Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by adding missing information. |